STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Companies Micro-Cap

Biodexa’s Acquisition of eRapa Marks Milestone in FAP Treatment Development

byLiliana Vida
April 26, 2024
in Micro-Cap, Pharmaceuticals
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Strategic Agreement with Emtora Biosciences Propels Biodexa’s Oncology Pipeline Forward with Potential to Transform Treatment Landscape

Biodexa Pharmaceuticals PLC (BDRX) has made a significant leap in the advancement of treatments for Familial Adenomatous Polyposis (FAP) with its exclusive license agreement for eRapa™ from Rapamycin Holdings Inc., operating as Emtora Biosciences. This strategic move positions Biodexa at the forefront of FAP treatment development, offering new hope to the estimated 100,000 individuals afflicted with this rare genetic disease in the U.S. and Europe.

The agreement grants Biodexa worldwide rights to eRapa™, a Phase 3 ready asset, along with $17 million in non-dilutive grant funding to support pivotal clinical trials. With the potential to delay or prevent surgical interventions for FAP patients, eRapa™ represents a promising breakthrough in addressing an unmet medical need in the treatment landscape.

Stephen Stamp, CEO and CFO of Biodexa, emphasized the transformative impact of acquiring a Phase 3 ready asset supported by substantial grant funding, underscoring the added value for stakeholders. The partnership with Emtora Biosciences, which has demonstrated excellence in advancing eRapa™ through Phase 2 trials, signifies a collaborative effort to bring innovative therapies to patients in need.

Stephen Dufilho, Executive Chairman of Emtora Biosciences, expressed gratitude for the decade-long effort to advance eRapa™ to this pivotal moment, highlighting the contributions of scientists, clinicians, investors, and biotech executives. The transaction with Biodexa marks a significant milestone in the journey to bring eRapa™ to patients, offering hope for improved treatment outcomes and quality of life for individuals affected by FAP.

Find original press release:Here

You might like this article:Alphabet Surpasses Expectations with Stellar First-Quarter Performance

Previous Post

Alphabet Surpasses Expectations with Stellar First-Quarter Performance

Next Post

FDA Approves Pfizer’s Beqvez Gene Therapy for Hemophilia B: A Milestone in Rare Disease Treatment

Related Posts

scientist

Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240

byLuca Blaumann
October 29, 2025
0

Achievement validates CAPTN-3 platform scalability and advances IM1240 toward first-in-human clinical trials in 2026 Purple Biotech (PPBT), a clinical-stage biotechnology...

Co-Diagnostics Expands Global Reach with New Saudi Joint Venture

byLuca Blaumann
October 27, 2025
0

CoMira Diagnostics to Localize PCR Manufacturing and Healthcare Innovation Across KSA and 18 MENA Countries Co-Diagnostics (CODX), a leading molecular...

chemistry-2

Replimune Reports Promising New Data for Acral Melanoma Treatment at ESMO 2025

byLuca Blaumann
October 20, 2025
0

RP1 combined with nivolumab shows meaningful tumor response in rare and aggressive skin cancer Replimune Group (REPL), a clinical-stage biotechnology...

Next Post
chemistry

FDA Approves Pfizer's Beqvez Gene Therapy for Hemophilia B: A Milestone in Rare Disease Treatment

Latest News

Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240

Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance

Nvidia Partners with U.S. Department of Energy to Build Seven AI Supercomputers

Qualcomm Enters the AI Data Center Battle with Powerful New AI200 and AI250 Chips

Co-Diagnostics Expands Global Reach with New Saudi Joint Venture

Based on Your Interest

investing
Artificial Intelligence

Datavault AI and Wellgistics Partner to Revolutionize Prescription Tracking with Blockchain Technology

October 24, 2025
trading-chart
Large-Cap

AMD Shares Surge as IBM Taps Its Chips for Quantum Computing Breakthrough

October 24, 2025
trading-chart
Large-Cap

Intel Surges After Strong Q3 Earnings Beat, But Manufacturing Challenges Remain

October 23, 2025

Recommended

Auto Manufacturers

Ford Beats Q3 Estimates but Cuts 2025 Outlook Following Supplier Fire

October 23, 2025
Biotechnology

Scienture Launches Commercial Sales of Arbli™, the First FDA-Approved Ready-to-Use Losartan Suspension

October 23, 2025
Auto Manufacturers

Earnings Season Heats Up as Tesla, Netflix, and Auto Giants Take Center Stage

October 23, 2025
Auto Manufacturers

Tesla’s Record Revenue Tops Forecasts

October 22, 2025
Foods

Beyond Meat’s (BYND) Rocky Road: Near-Term Opportunity or Caution Ahead?

October 22, 2025
Stoxpo

Follow us on social media:

Highlights

  • Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240
  • Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance
  • Nvidia Partners with U.S. Department of Energy to Build Seven AI Supercomputers
  • Qualcomm Enters the AI Data Center Battle with Powerful New AI200 and AI250 Chips
  • Co-Diagnostics Expands Global Reach with New Saudi Joint Venture

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

scientist

Purple Biotech Reaches Key Manufacturing Milestone for Groundbreaking Tri-Specific Antibody IM1240

October 29, 2025

Orion Group Holdings Delivers Strong Q3 Results and Raises 2025 Guidance

October 28, 2025
nvidia-chip

Nvidia Partners with U.S. Department of Energy to Build Seven AI Supercomputers

October 28, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.